Therapeutic Antibody Pioneers Professor Sir Marc Feldmann and Dr. H. Michael Shepard Formally Launch Enosi Life Sciences

The Company will focus on second generation therapeutics for cancer and autoimmune diseases based on their previous successes

SAN DIEGO, Sept. 02, 2020 (GLOBE NEWSWIRE) — World-renowned scientists Professor Sir Marc Feldmann and Dr. H. Michael Shepard are pleased to announce the formal launch of Enosi Life Sciences (Enosi), a company generating industry-leading scientific solutions to provide improved therapeutic approaches for autoimmune diseases and cancer.

Feldmann and Shepard have developed some of the most successful and profitable therapeutics available today and are recognized pioneers in the therapeutic antibody field, receiving multiple accolades including the most prestigious honor in U.S. medicine: The Albert Lasker award.

These experts will combine their talents, networks and experience to address the growing global health challenges of autoimmune diseases, cancer and acute inflammatory conditions. Enosi will initially develop a series of therapeutics for enhanced treatment of autoimmune diseases. The initial product candidates are:

  • EN1001: A TNF Receptor 1 binding protein that inhibits the inflammatory TNFR1 without affecting the anti-inflammatory TNF Receptor 2’s healing capabilities.
  • EN2001: A first-in-class therapy that complements all current anti-TNF drugs by targeting the co-driver of rheumatoid arthritis (RA). This multi-specific antibody receptor fusion protein traps inflammatory growth factors that are also important in cancer.

Currently available anti-TNF drugs block both the TNFR1 and TNFR2 pathways. The inability to separate the inflammatory from the anti-inflammatory blocking capabilities limits efficacy and can increase the risk of opportunistic infections. Enosi’s EN1001 and EN2001 solutions will precisely target and inhibit only TNFR1 and the co-driver of RA, bringing a more effective and focused treatment to the market.

“We are excited to announce the formal launch of Enosi and believe the leadership team’s combined talents will accelerate the development of new and more effective therapeutics for both cancer and autoimmune diseases,” said Dr. H. Michael Shepard, President and CSO of Enosi Life Sciences. “These two separate areas of medicine have an important link, inflammation, and we are able to create a specific therapeutic antibody that only blocks TNFR1 receptors – an approach that is completely novel in the therapeutic market.”

“At Enosi, we have created a visionary approach to the way cancer and autoimmune diseases are researched and treated. We’ve been here before as Mike, myself and other members of our leadership team have all been a part of the successful research and development process in this field,” said Sir Marc Feldmann, Co-Founder and Board Member of Enosi Life Sciences. “We know what big pharma is and is not doing, we understand how the process works and what to look for in a successful drug candidate, and most importantly, our connections within the research community allow us to increase program awareness, incorporate key opinion leaders, and get our solutions in the hands of clinical research teams.”

Dr. Shepard is renowned as a leading global authority on cancer research and multipurpose therapeutics for his work in creating Herceptin, the first monoclonal antibody to treat cancer. Sir Feldmann helped develop Infliximab, the first anti-TNF therapeutic to show dramatic results for autoimmune diseases.

To learn more about Enosi Life Sciences, please visit www.enosi-life.com.

About Enosi Life Sciences
Enosi Life Sciences is a drug research and development company focused on providing industry-leading therapeutics for autoimmune diseases and cancer. The company was founded by world-renowned scientists Professor Sir Marc Feldmann, who discovered anti-tumor necrosis factor (anti-TNF) therapy as an effective treatment for rheumatoid arthritis and other autoimmune diseases (Lasker Award, 2003); and Dr. H. Michael Shepard, whose research in humanized antibodies created the first monoclonal antibody therapy targeting cancer oncogene encoded-proteins (Lasker award, 2019). Enosi Life Sciences consolidates Feldmann and Shepard’s expertise in cancer and autoimmune diseases with a unique combination of medical, scientific and management expertise to expand therapeutic options from its executive team. To learn more about Enosi Life Sciences, visit www.enosi-life.com.

Company Contact
Ozan Pamir
CFO
ozan@enositherapeutics.com
858-350-4392

IR Contact
Tom Becker
Enosi Life Sciences
investment@enositherapeutics.com
702-445-7038

Media Relations Contact
Kate Caruso-Sharpe
FischTank PR
enosi@fischtankpr.com
646-699-1534

Group 3 Copy 2

James N. Woody

Executive Chairman

  • Jim brings more than 25 years of pharmaceutical research and management experience to Enosi.
  • In addition to his duties as a consultant to LVP, where he served as a General Partner for 14 years, Jim is currently Chairman of Viracta Therapeutics, a company focusing on unique therapies for virally induced cancers.  
  • He was the founding CEO of OncoMed Pharmaceuticals, a cancer therapeutic antibody company. He was the Board member for both ForteBio, and Protein Simple, both successfully acquired. Jim was formerly President and GM of Roche Bioscience (former Syntex) in Palo Alto, CA. 
  • Previously, Jim served as Chief Scientific Officer and Senior Vice President of R&D for Centocor. While at Centocor, Jim’s team developed the blockbuster drug Remicade. 
  • Jim served as a Navy Medical Officer, and was Head of the Navy Transplant Research Program. With his colleagues and with both Navy and Congressional support, founded the National Marrow Donor Program. 
  • He was promoted to Commanding Officer and Director, US Naval Medical Research and Development Command in Bethesda Maryland. He was responsible for the surveillance, detection and therapy for all Biologic Warfare Agents and Infectious Diseases in the first Gulf War and was awarded the Marine Corps/US Navy Legion of Merit for his service. 
  • Jim served as Chairman of the Silicon Valley Leadership Group representing over 120 Silicon Valley Companies, is a board member of the Lucile Packard Children’s Hospital (Stanford).
  • Jim holds an M.D. from Loma Linda University, trained in Pediatric Immunology at Duke University and Children’s Hospital in Boston (Harvard), and holds a Ph.D. in Immunology from the University of London, England. He was Professor of Pediatrics and Microbiology at Georgetown University School of Medicine 1982-1996. He has authored or co-authored over 140 publications.
Group 3 Copy

H. Michael Shepard, Ph.D.

CEO & Co-founder

  • Dr. H. Michael Shepard is a global, leading authority on cancer research and therapeutics.
  • Best known for his invention of “Herceptin”/Trastuzumab, which has remained one of the most profitable platforms for Roche (>$7B USD).
  • Dr. Shepard is a highly-experienced and respected leader with many successful ventures in this field – working at Genentech (sold to Roche – $46.8 B USD), Canji, Inc. (bought by Scheirng-Plough) and Halozyme (now valued at $2.6B USD).
  • Widely acknowledged biomarker pioneer and recognized worldwide, Dr. Shepard has received the 2019 Albert Lasker Award and the Warren Alpert Prize, among many other professional accolades.

Enosi Team SirMarc Lasker Circle

Sir Marc Feldmann, M.D. Ph.D.

Director & Co-founder

  • Sir Marc Feldmann is a preeminent immunologist, and an Emeritus Professor at the University of Oxford.
  • With Sir Ravinder Maini, identified TNF as a target. Trials of Infliximab (Remicade) they led were successful, and prompted J&J’s $4.9B USD acquisition of Centocor.
  • Anti-TNF sales > $50B USD globally.
  • Professor Sir Marc Feldmann is a Fellow of the Royal Society , of Australian Academy and a Foreign Member of the US National Academy of Sciences; he was knighted in 2010 and received the Australian equivalent.
  • He has received many accolades including the Albert Lasker Award, the Crafoord Prize, the Canada Gairdner Award, the Paul Janssen Award, the Ernst Schering Award.